Moleculin Biotech Inc
Research Moleculin Biotech Inc (MBRX) on Bullrun: market cap USD 3.26M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMBRX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.26M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 12.85M
- Free cash flow-USD 6.11M
Valuation Snapshot
latest market cap is USD 3.26M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 33.56M | -USD 22.74M | n/a | -74.92 | USD 8.88M | USD 359.00K | USD 15.01M |
| FY2024 | USD 0 | -USD 26.05M | -USD 23.88M | n/a | -81.29 | USD 4.28M | USD 478.00K | USD 11.21M |
| FY2023 | USD 0 | -USD 29.77M | -USD 23.72M | n/a | -25.12 | USD 23.55M | USD 574.00K | USD 30.93M |
| FY2022 | USD 0 | -USD 29.03M | -USD 27.71M | n/a | n/a | USD 43.15M | USD 486.00K | USD 52.19M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.26M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 6.85M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 5.75M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 28.67M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 30.33M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 53.15M | n/a | n/a | n/a |
About Moleculin Biotech Inc
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Moleculin Biotech Inc's market cap?
Moleculin Biotech Inc's market capitalization is USD 3.26M.
What does Moleculin Biotech Inc do?
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.